

School of Natural Sciences and Mathematics

The Vascular Disrupting Agent Combretastatin A-4 Phosphate Causes Prolonged Elevation of Proteins Involved in Heme Flux and Function in Resistant Tumor Cells--Supplement

UT Dallas Author(s):

Sanchareeka Dey
Sarada Preeta Kalainayakan
Poorva Ghosh
Keely E. FitzGerald
Li Zhang

Rights:

CC BY 3.0 (Attribution)
©2017 The Authors


Citation:

Dey, Sanchareeka, Sharda Kumari, Sarada Preeta Kalainayakan, James Campbell III, et al. 2018. "The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells." *Oncotarget* 9(3), doi:10.18632/oncotarget.23734


This document is being made freely available by the Eugene McDermott Library of the University of Texas at Dallas with permission of the copyright owner. All rights are reserved under United States copyright law unless specified otherwise.

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells

SUPPLEMENTARY FIGURES



Supplementary Figure 1: Dynamic BLI, following subcutaneous administration of luciferin on each occasion, showing tumor response at different time points (0h, 3h, and 24h) post-saline (control) or CA4P administration (120 mg/kg, IP). Note that the tumor vasculature was shut down 3 hours after CA4P administration, and therefore, the substrate luciferin could not reach the tumor, causing the absence of luminescence signals.



Supplementary Figure 2: CA4P affects expression of hemoproteins and putative heme sensor. Representative images of CA4P-treated, fluorescent immunohistochemically stained paraffin sections of subcutaneous xenograft tumors including untreated control (Row 1), 3 hours post-CA4P (Row 2), and 24 hours post-CA4P (Row 3). Bar graphs indicate the quantification of mean grey intensity. Data are presented as mean \pm SEM (n=10, *p value < 0.05; **p value < 0.005; scale bar, 20 μ m). **(A)** cytochrome c is significantly elevated 3 hours after treatment. At 24 hours post-treatment, it is not significantly different from untreated tumors. Anti-cytochrome c antibody (green), DAPI for nuclei (blue), and merged image (green and blue). **(B)** COX-2 is significantly enhanced at both 3 and 24 hours post-treatment, with higher expression at 24 hours post-treatment. Anti-COX-2 antibody (green), DAPI for nuclei (blue), and merged image (green and blue). **(C)** PGRMC1 is elevated significantly at 3 hours post-treatment. PGRMC1 level are similar to those of untreated tumors at 24 hours post-treatment. Anti-PGRMC1 antibody (red), DAPI for nuclei (blue), and merged image (red and blue).